-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
The active pharmaceutical ingredient of levalbuterol hydrochloride developed by Shijiazhuang Sihua Pharmaceutical Group has been approved.
Category:
发布时间：2023-09-04
【概要描述】
Recently, levalbuterol hydrochloride developed by Hebei Guangxiang Pharmaceutical Co., Ltd., a subsidiary of Shijiazhuang Sihua Pharmaceutical Group, has been approved by the National Medical Products Administration and registered as an active pharmaceutical ingredient for use in marketed dosage forms, making the company the third in China to receive approval to manufacture this product. To date this year, the group has secured approval for a total of 43 new products.
Recently, levalbuterol hydrochloride developed by Hebei Guangxiang Pharmaceutical Co., Ltd., a subsidiary of Shijiazhuang Sihua Pharmaceutical Group, has been approved by the National Medical Products Administration and registered as an active pharmaceutical ingredient for use in marketed dosage forms, making it the third domestic pharmaceutical company to receive approval for the production of this product. To date, the group has secured approval for a total of 43 new products so far this year.
It is reported that levalbuterol hydrochloride is an adrenergic β2-receptor agonist primarily used for the treatment of bronchial asthma and chronic obstructive pulmonary disease.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091